Importantly, trigonelline demonstrated selective toxicity toward cancer cells without harming normal tissues, underscoring its therapeutic potential as an Nrf2-targeting adjuvant in ferroptosis-based strategies for HNC. This evidence concerns the gene NFE2L2 and cancer.